Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

As with many early-stage companies, Vaccinex funnelled the majority of its resources into a lead candidate. The asset, called ...

It's hard to trust the disease statistics when cognitive tests often are not completed, write Robert Brownell and Dr. Yogesh ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

Diagnosing Alzheimer's disease before people have any symptoms is possible, but brings up concerns when so few treatments are ...

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

There are now two fully approved drugs on the market that can, sometimes, slow down the progression of Alzheimer's disease.

"I think it helped," says her husband, Ken Bell. "But I'm not sure." That sort of uncertainty is common when it comes to ...